5 Questions on Melanoma

“VIKTORIA-1 is the first study to demonstrate a statistically significant and clinically meaningful improvement in PFS with PAM inhibition in patients with PIK3CA wild-type disease, all of whom received prior CDK4/6 inhibition,” said Barbara Pistilli, MD.

Experts share updated results on investigational hematologic oncology regimens that they presented at the 2025 ASH Meeting.

Data from the PREFER study may provide evidence for improving oncofertility counseling for premenopausal women with early breast cancer.

Daniel C. McFarland, DO; and Charles S. Kamen, PhD, MPH, focused on cultural humility, nonverbal data collection, and tailored resources to improve care.

The risk of pain deterioration was similar with T-DXd/pertuzumab vs standard of care in the DESTINY-Breast09 trial.

Data from a phase 1 trial may support additional clinical studies of CT0596 in relapsed/refractory multiple myeloma.